Predictive Gene Signature Selection for Adjuvant Chemotherapy in Non-Small Cell Lung Cancer Patients
نویسندگان
چکیده
........................................................................................................................................... i Acknowledgement ......................................................................................................................... iii Table of
منابع مشابه
A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients.
PURPOSE Prospectively identifying who will benefit from adjuvant chemotherapy (ACT) would improve clinical decisions for non-small cell lung cancer (NSCLC) patients. In this study, we aim to develop and validate a functional gene set that predicts the clinical benefits of ACT in NSCLC. EXPERIMENTAL DESIGN An 18-hub-gene prognosis signature was developed through a systems biology approach, and...
متن کاملPrognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer.
PURPOSE The JBR.10 trial demonstrated benefit from adjuvant cisplatin/vinorelbine (ACT) in early-stage non-small-cell lung cancer (NSCLC). We hypothesized that expression profiling may identify stage-independent subgroups who might benefit from ACT. PATIENTS AND METHODS Gene expression profiling was conducted on mRNA from 133 frozen JBR.10 tumor samples (62 observation [OBS], 71 ACT). The min...
متن کاملEfficacy of adjuvant chemotherapy for non-small cell lung cancer assessed by metastatic potential associated with ACTN4
Although several clinical trials have demonstrated the benefits of platinum-combined adjuvant chemotherapy for resected non-small cell lung cancer (NSCLC), predictive biomarkers for the efficacy of such therapy have not yet been identified. Selection of patients with high metastatic ability in the early stage of non-small cell lung cancer (NSCLC) has the potential to predict clinical benefit of...
متن کاملComparing Docetaxel Plus Cisplatin with Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients with Advanced Non-Small-Cell Lung Cancer: a Single Institute Study
Aims: The backbone of treatment in advanced non-small cell lung cancer is platinum-based doublet chemotherapy. We intended to compare the effectiveness of two commonly used regimens in real world practice. Methods: This single institute, parallel comparative post marketing study included 100 patients with chemo-naïve advanced (stage IIIB, IV) non-small cell lung cancer and Eastern Cooperative O...
متن کاملComparison of two ERCC1 antibodies as prognostic and predictive biomarkers for early non-small cell lung cancer.
AIM Expression of excision repair cross-complementing rodent repair deficiency, complementation group 1 (ERCC1) was suggested to be of predictive value for selecting patients with clinical benefit from platinum-based chemotherapy. PATIENTS AND METHODS In order to validate the prognostic and predictive value of ERCC1, we comparatively analyzed 298 patients with non-small cell lung cancer (NSCL...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2014